Drugs / Encepur Adults
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT00161824 | Oct 2001 → Jan 2002 | tick-borne encephalitis | Pfizer | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03294135 | Oct 2017 → Oct 2021 | viral infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Encepur Adults | “The purpose of this study is to assess the safety of a vaccination schedule consisting of two vaccinations (21-35 days apart) with the tick-borne encephalitis (TBE) vaccine...” NCT00161824 ↗ |
| Modality | Vaccine | “another licensed TBE vaccine (Encepur® adults, with polygeline)” NCT00161824 ↗ |
| Route | Intramuscular | “administered intramuscularly” NCT03294135 ↗ |